1 May 2010Biotechnology

What next for stem cell research?

When, in the course of case G2/06 (the WARF application), the Enlarged Board of Appeal of the European Patent Office (EPO) was invited to seek the assistance of the Court of Justice (the court) in construing Article 6 of the Biotechnology Directive, it must have come as no surprise to observers that it declined this invitation. The enlarged board was not persuaded by the potential awkwardness of the court subsequently reaching an alternative view as to the patentability of embryonic stem cell lines.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Gilead to pay up to $5bn for antibody-drug conjugates push

8 April 2026 The acquisition of Munich-based biotech gives Gilead ownership of proprietary ADCs tech at a time when pharma and biotech companies are racing to secure next-generation cancer treatments.

Biotechnology

Closing the women's health gap offers ‘benefits for all’

7 April 2026 On World Health Day 2026, despite data trending in the right direction, systemic barriers continue to limit female inventors—and women's health is suffering.

Biotechnology

Novartis bets $2bn on biologics as Xolair patents fade

27 March 2026 The Swiss pharma giant targets next-generation anti-IgE biologics as it looks to extend its dominance in the market.